Name (Synonyms) | Correlation | |
---|---|---|
drug1332 | Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST) Wiki | 1.00 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Background: Oropharyngeal dysphagia (OD) is a common complication in/post ICU patients that have been with intubation/mechanical ventilation or with tracheotomies or NG tubes, in patients with acute respiratory infection/pneumonia/respiratory insufficiency with a severe disease needing high concentration of oxygen or noninvasive mechanical ventilation and also in patients discharged from acute hospitals to rehabilitation centers, nursing homes or other facilities. All these situations are common for COVID-19 patients that are currently filling our hospitals due to the pandemic expansion of SARS-CoV-2. OD is associated to prolonged hospitalization, dehydration and severe nutritional and respiratory complications -aspiration pneumonia-, hospital readmissions and mortality. Aim: to assess the prevalence of OD in these patients and to know their needs of compensatory treatment. Methods: observational study in which we will use the volume-viscosity swallowing test (V-VST) to assess the prevalence of OD in admitted patients with confirmed COVID-19 at the Consorci Sanitari del Maresme. We will register also results of the EAT-10, nutritional status (MNA-sf/MUST/NRS), the needs of compensatory treatments of these patients (fluid and nutritional adaptation and use of nutritional supplements) and clinical complications during 6 months follow up.
Description: Prevalence of oropharyngeal dysphagia according to a clinical assessment tool, the Volume-Viscosity Swallowing Test (V-VST).
Measure: Prevalence of oropharyngeal dysphagia Time: From April to July 2020.Description: Eating assessment tool (EAT-10 score). A tool that goes from 0 to 40 points and indicates that the patient is at risk of oropharyngeal dysphagia if he/she presents 3 or more points
Measure: Swallowing screening Time: From April to July 2020.Description: Percentage of patients with impairements in efficacy and/or safety of swallow.
Measure: Swallowing status. Time: From April to July 2020.Description: Nutritional status of study patients (% malnourished, at risk of malnutrition or wellnourished).
Measure: Nutritonal status of study patient's. Time: From April to July 2020.Description: Fluid (volume and viscosity) requirements of study patients.
Measure: Needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation). Time: From April to July 2020.Description: Nutritional adaptation requirements (type of diet and need of nutritional supplementation).
Measure: Needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation). Time: From April to July 2020.Description: Incidence of hospital readmissions: number of hospital readmissions/patient/6 months.
Measure: Clinical complications at 6 months follow up from patient's medical history (incidence of readmissions). Time: 6 months from inclusion.Description: Prevalence: % of patients with hospital readmissions during the follow-up.
Measure: Clinical complications at 6 months follow up from patient's medical history (prevalence of readmissions). Time: 6 months from inclusion.Description: Incidence: number of visits to the emergency department/patient/6 months.
Measure: Clinical complications at 6 months follow up from patient's medical history (number of visits to emergency department). Time: 6 months from inclusion.Description: Prevalence: % of patients visiting the emergency department during the follow-up.
Measure: Clinical complications at 6 months follow up from patient's medical history (percentage of visits to emergency department). Time: 6 months from inclusion.Description: Incidence of respiratory infections (including pneumonia, and COPD exacerbations).
Measure: Clinical complications at 6 months follow up from patient's medical history (respiratory complications). Time: 6 months from inclusion.Description: 6 months mortality.
Measure: Clinical complications at 6 months follow up from patient's medical history (mortality). Time: 6 months from inclusion.